Compare Heron Therapeutics Inc (HRTX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs VF Corp — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while VF Corp trades at $15 (market cap $5.71B). The key difference: VF Corp is far larger — about 84× Heron Therapeutics Inc's market cap, and VF Corp pays a 2.48% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and VF Corp for 64 Days on average.
| HRTX | VFC | |
|---|---|---|
Market Cap | $68.01M | $5.71B |
Volume | 1,891,941 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $21.55 |
52-Week Low | $0.27 | $12.62 |
Typical Hold Time | 35 Days | 64 Days |
Enterprise Value | $174.75M | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
VFC trades at $14.38, down 0.48% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock is near its 52-week low, reflecting ongoing challenges. Recent earnings have been volatile, with two misses in the last three quarters, and the company reported a net loss of $189.72 million for 2025. Revenue has declined from $11.8 billion in 2022 to $9.5 billion in 2025, though 2026 projects a return to profitability.
The outlook for VFC hinges on executing its turnaround amid weak Vans performance. The stock's discounted valuation (P/E of 20.84, P/S of 0.6) offers potential upside if brand recovery gains traction, but high execution risk and competitive pressures pose significant threats. Analyst consensus is mixed with a Hold rating, and the stock faces near-term resistance at $15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
